1 / 5

Primary and Other Outcomes: DREAM

Primary and Other Outcomes: DREAM.

clay
Download Presentation

Primary and Other Outcomes: DREAM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Primary and Other Outcomes: DREAM Data are number (%). *Rows are not mutually exclusive for components of the composite—if a participant had more than one component of the composite then they are counted in the relevant row. †Regression implies achieving a normal fasting glucose concentration (as defined in both rows) and 2-h plasma glucose level. FPG = fasting plasma glucose. OGTT = oral glucose tolerance test. DREAM investigators. Lancet 2006;368:1096-1105.

  2. Primary and Other Outcomes: DREAM(cont’d) Data are number (%). *Rows are not mutually exclusive for components of the composite—if a participant had more than one component of the composite then they are counted in the relevant row. †Regression implies achieving a normal fasting glucose concentration (as defined in both rows) and 2-h plasma glucose level. ‡Defined as acute treatment with at least two of the following criteria: typical signs and symptoms, typical radiological evidence, use of diuretics, vasodilators, or inotropes. DREAM investigators. Lancet 2006;368:1096-1105.

  3. Adverse Events, Hospitalization, and Death: ADOPT † P<0.05 for the comparison between this treatment group and the rosiglitazone group; ‡ P<0.01 for the comparison between this treatment group and the rosiglitazone group. ADOPT study group. N Engl J Med 2006;355:2427-2443.

  4. Laboratory Assessment and Concomitant Use of Cardiovascular Drugs: ADOPT ¶ All laboratory values are mean values at 4 years; † P<0.05 for the comparison between this treatment group and the rosiglitazone group; ‡ P<0.01 for the comparison between this treatment group and the rosiglitazone group. ADOPT study group. N Engl J Med 2006;355:2427-2443.

  5. Rates of Myocardial Infarction and Death from Cardiovascular Causes Nissen and Wolski. N Engl J Med 2007;356:2457-2471.

More Related